LLY

767.89

+0.19%↑

JNJ

154.84

+0.84%↑

ABBV

190.01

+1%↑

UNH

299.18

-0.16%↓

ABT

133.97

+0.84%↑

LLY

767.89

+0.19%↑

JNJ

154.84

+0.84%↑

ABBV

190.01

+1%↑

UNH

299.18

-0.16%↓

ABT

133.97

+0.84%↑

LLY

767.89

+0.19%↑

JNJ

154.84

+0.84%↑

ABBV

190.01

+1%↑

UNH

299.18

-0.16%↓

ABT

133.97

+0.84%↑

LLY

767.89

+0.19%↑

JNJ

154.84

+0.84%↑

ABBV

190.01

+1%↑

UNH

299.18

-0.16%↓

ABT

133.97

+0.84%↑

LLY

767.89

+0.19%↑

JNJ

154.84

+0.84%↑

ABBV

190.01

+1%↑

UNH

299.18

-0.16%↓

ABT

133.97

+0.84%↑

Search

Novo Nordisk A-S

Avatud

SektorTervishoid

74.74 2.38

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

72.3

Max

75.15

Põhinäitajad

By Trading Economics

Sissetulek

804M

29B

Müük

-7.6B

78B

P/E

Sektori keskmine

20.344

51.198

Aktsiakasum

6.53

Dividenditootlus

2.22

Kasumimarginaal

37.182

Töötajad

77,406

EBITDA

5.9B

46B

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+27.46% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

2.22%

2.40%

Turustatistika

By TradingEconomics

Turukapital

55B

321B

Eelmine avamishind

72.36

Eelmine sulgemishind

74.74

Uudiste sentiment

By Acuity

30%

70%

83 / 380 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

Novo Nordisk A-S Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

16. mai 2025, 11:36 UTC

Peamised uudised

Novo Nordisk CEO to Step Down Amid Market Challenges

12. mai 2025, 09:36 UTC

Suurimad hinnamuutused turgudel

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

7. mai 2025, 11:29 UTC

Peamised uudised
Tulu
Suurimad hinnamuutused turgudel

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs -- 2nd Update

7. mai 2025, 07:05 UTC

Tulu

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales -- Update

7. mai 2025, 06:19 UTC

Tulu

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales

3. juuni 2025, 15:03 UTC

Omandamised, ülevõtmised, äriostud

Hims & Hers Seeks Growth in Europe as Weight-Loss Business Shifts -- Barrons.com

29. mai 2025, 01:00 UTC

Peamised uudised

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

20. mai 2025, 14:08 UTC

Tulu

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

20. mai 2025, 07:43 UTC

Market Talk

Novo Nordisk Guidance at Risk After CEO News -- Market Talk

16. mai 2025, 18:35 UTC

Peamised uudised

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16. mai 2025, 17:34 UTC

Peamised uudised

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 2nd Update

16. mai 2025, 13:42 UTC

Kuumad aktsiad

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials -- WSJ

16. mai 2025, 13:27 UTC

Market Talk

Novo Nordisk CEO Departure Comes as a Surprise -- Market Talk

16. mai 2025, 13:15 UTC

Peamised uudised

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- Update

16. mai 2025, 12:17 UTC

Tulu

Novo Nordisk Chairman: No Link Between CEO Change and Other Recent Exec Departures

12. mai 2025, 22:14 UTC

Peamised uudised

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12. mai 2025, 18:45 UTC

Peamised uudised

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12. mai 2025, 12:07 UTC

Market Talk

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12. mai 2025, 07:20 UTC

Market Talk

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

7. mai 2025, 15:13 UTC

Tulu

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Arista, Sarepta, Charles River, and More -- Barrons.com

7. mai 2025, 13:56 UTC

Tulu

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7. mai 2025, 13:45 UTC

Tulu

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Nordisk, Sarepta, EA, Upstart, and More -- Barrons.com

7. mai 2025, 11:25 UTC

Tulu

These Stocks Are Moving the Most Today: Super Micro, AMD, Disney, Uber, Novo Nordisk, Sarepta, EA, Tesla, and More -- Barrons.com

7. mai 2025, 11:18 UTC

Tulu

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7. mai 2025, 09:55 UTC

Tulu

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Disney, and More -- Barrons.com

7. mai 2025, 09:36 UTC

Tulu

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Tesla, and More -- Barrons.com

7. mai 2025, 09:04 UTC

Tulu
Kuumad aktsiad

Stocks to Watch Wednesday: Disney, Uber, Super Micro -- WSJ

7. mai 2025, 08:10 UTC

Market Talk

Novo Nordisk Cuts Guidance Slightly More Than Expected -- Market Talk

7. mai 2025, 08:08 UTC

Market Talk

Novo Nordisk's Downgraded Guidance Assumes Large Wegovy Uplift in 2H -- Market Talk

7. mai 2025, 07:11 UTC

Market Talk
Tulu

Novo Nordisk Shares Seen Under Pressure After Downgrade -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Novo Nordisk A-S Prognoos

Hinnasiht

By TipRanks

27.46% tõus

12 kuu keskmine prognoos

Keskmine 92.6 USD  27.46%

Kõrge 139.59 USD

Madal 61 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Novo Nordisk A-S 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

8 ratings

3

Osta

4

Hoia

1

Müü

Tehniline skoor

By Trading Central

62.63 / 69.23Toetus ja vastupanu

Lühikene perspektiiv

Weak Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

83 / 380 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.